Ben Hargreaves finds that a new line of attack could be the development of more effective non-opioid painkillers, with one potential therapy moving closer to approval. The opioid epidemic in the ...

agonist in phase 1 testing that also has potential as a non-opioid painkiller. Lilly's Zepbound has become the first drug approved by the FDA for obese patients with obstructive sleep apnoea ...

A new scientific review of 148 studies enrolling over 4.3 million adult chronic pain patients treated with prescription opioid painkillers ... patients with chronic non cancer pain: a systematic ...

The funds come from a $26 billion multistate court settlement reached with companies linked to distributing and manufacturing prescription painkillers linked to the opioid epidemic. The companies ...

Distribution and nonmedical use of prescription painkillers is prohibited by federal law, but off-the-label abuse has grown into a nationwide epidemic. The most troubling drugs are opioids, or ...

The market for non-opioid painkillers is booming in the wake of a devastating overdose crisis and an opioid industry far diminished from its heyday. Companies offering nonsurgical alternatives to ...

Mallinckrodt, the nation’s biggest opioid pill maker, agreed to pay $1.7 billion in opioids damages in 2022 in its first ...

Doctors can then recommend that those with a higher risk use non-opioid pain relievers rather ... to take these medications is highly personal, strong evidence supports their use.

A jury in November ordered the companies to pay $266 million for flooding Baltimore with hundreds of millions of addictive opioid painkillers from 2006 to 2019. Now it’s up to Circuit Judge ...

UBS analyst Ashwani Verma raised the firm’s price target on Teva (TEVA) to $28 from $26 and keeps a Buy rating on the shares.